Upanovimab

尤帕韦单抗

Report date: 2025/11/17 20:01:59

Base Information

Drug NameUpanovimab
Drug Alias NameAnti-SARS-CoV-2 Monoclonal AntibodySCTA-01HB-27
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMexicoArgentina +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPending
Originator CompaniesSinoCelltech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A